AMILI
Asia's leading microbiome precision medicine company, developing gut microbiome-based diagnostics, therapeutics, and personalized nutrition solutions.
Website
https://www.amili.asiaLocation
Singapore
Founded
2019
Investors
1
Categories
microbiome, precision-medicine, biotech, asia-pacific
Notes
AMILI (Asian Microbiome Library Initiative) is Asia's leading microbiome company focused on precision medicine applications. The company has built Asia's largest gut microbiome database and is developing microbiome-based solutions for diagnostics, therapeutics, and personalized nutrition.
The company leverages its Asian-specific microbiome data to develop products tailored to Asian populations, whose gut microbiomes differ significantly from Western populations due to dietary and genetic factors.
Team
- Jeremy Lim, M.D. - Co-founder & CEO
- LinkedIn: linkedin.com/in/jeremylim
- Scientific team specializing in microbiome research
Additional Research Findings
- In TVM Capital Healthcare portfolio
- Asia's largest gut microbiome database
- Focus on Asian-specific microbiome profiles
- Products include microbiome testing and personalized recommendations
- Developing microbiome-based therapeutics
- Headquarters in Singapore with regional presence
- Addressing unique Asian gut microbiome characteristics
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| TVM Capital Healthcare | Dubai, UAE & Munich, Germany | biotech-focused | series-aseries-b+1 | 10 |